Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accumulated Expenses (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Accumulated Expenses for 4 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 50.23% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 50.23% year-over-year, with the annual reading at $2.0 million for FY2025, 50.23% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $2.0 million at Mereo BioPharma, down from $4.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $5.5 million in Q4 2023, with the low at $2.0 million in Q4 2025.
  • Average Accumulated Expenses over 4 years is $3.9 million, with a median of $3.9 million recorded in 2024.
  • Peak annual rise in Accumulated Expenses hit 35.47% in 2025, while the deepest fall reached 50.23% in 2025.
  • Over 4 years, Accumulated Expenses stood at $5.4 million in 2022, then increased by 0.57% to $5.5 million in 2023, then dropped by 25.54% to $4.1 million in 2024, then crashed by 50.23% to $2.0 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $2.0 million, $4.1 million, and $5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.